CagriSema and Menopause: What the Research Shows
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
CagriSema menopause research currently includes exploratory analyses of an earlier weight-management trial. The October 2026 report describes weight changes across reproductive stages. It does not establish CagriSema as a treatment for menopause symptoms, hormone imbalance or endometriosis. Original sponsor report.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs and sells research materials. This is commercially interested, AI-assisted editorial content, not an independent scientific review. The sponsor's conference summary, the original parent-trial abstract and trial record were checked November 16, 2026. The full subgroup posters, individual data and full parent manuscript were not independently reviewed. This article offers no treatment or product-use recommendation.

Which study do the menopause findings come from?
REDEFINE 1 was a Novo Nordisk-funded randomized 68-week trial involving 3,417 adults without diabetes. Participants received the cagrilintide-semaglutide combination, an individual component or placebo, with lifestyle support. The main publication reported weight outcomes and safety across the overall population. Original REDEFINE 1 report.
The menopause findings are later analyses of that trial. They should not be presented as a newly randomized trial designed specifically to compare reproductive stages. The trial record provides context for the original objectives and eligibility.
What did the exploratory analysis report?
Novo's October 20 announcement described estimated weight reduction at week 68 under an adherence-based efficacy analysis:
Retrospectively classified group | Participants: CagriSema / placebo | CagriSema reduction | Placebo reduction |
|---|---|---|---|
Premenopausal | 408 / 122 | 26.7% | 2.1% |
Perimenopausal | 256 / 81 | 24.8% | 1.7% |
Postmenopausal | 530 / 168 | 23.1% | 2.6% |
The sponsor describes 1,902 women in this post hoc comparison of CagriSema with placebo, including a separately reported hormone-therapy group. Menopause status was inferred after the fact using age, medical history and recorded symptoms, rather than prospective reproductive staging or biochemical confirmation. Hormone-therapy users were evaluated separately. Formal treatment-by-subgroup interaction testing was not performed, and reported p-values were not adjusted for multiple comparisons. Sponsor's subgroup methods and results.
Consequently, the numerical ordering cannot establish that menopause itself caused different responses. These are hypotheses for further study.
Why the parent-trial result is different
The original report estimated overall weight change of −20.4% with the combination versus −3.0% with placebo using a treatment-policy approach. Gastrointestinal adverse events affected 79.6% and 39.9%, respectively, and were mostly transient and mild to moderate. Parent-trial abstract.
Those figures describe the overall trial and a different analysis. They should not be compared directly with a selected subgroup's adherence-based estimate as if one were a correction of the other. The subgroup figures also do not provide menopause-stage-specific safety rates.
The newer REDEFINE 9 article illustrates another reason to keep trial identity and analysis methods beside each percentage.
What does a post hoc analysis tell us?
“Post hoc” means the analysis was developed after the main study design. Such work can identify questions that deserve a dedicated test, but it requires care when interpreting differences between subgroups.
Our reading checklist is:
Classification: Was the characteristic measured directly and consistently?
Comparison: Was a difference between subgroups actually tested, rather than inferred from separate averages?
Other explanations: Could age, starting weight, health status or other variables explain an apparent pattern?
Multiplicity: Were many analyses performed, increasing the opportunity for chance findings?
Replication: Does a separate, prospectively designed study reproduce the pattern?
This is an editorial framework for reading evidence. It is not a reanalysis of participant-level results. See our guide to study design and endpoints.
What women's-health research would we like to see?
A useful follow-up would define reproductive stage before analysis, record hormone-therapy use clearly, and prespecify comparisons. It should measure safety and outcomes beyond the scale, such as physical function and quality of life, without assuming that one weight result answers every health question.
Bio Peptides Labs presents these as research priorities. We do not claim to conduct these trials or to have validated a combination for women. Our muscle-preservation guide explains why tissue measurements and function need separate assessment.
Does this show CagriSema treats menopause?
No. Weight outcomes in retrospectively classified groups cannot establish an effect on hot flashes, hormone levels or other menopause symptoms. Those claims require studies that measure the relevant outcomes.
Does this establish a benefit for endometriosis?
No. Endometriosis is a different clinical question. Our GLP-1 and endometriosis evidence review separates research possibilities from demonstrated treatment effects.
Are the findings specific to retatrutide?
No. These analyses concern cagrilintide with semaglutide. They cannot be transferred to a different molecule on the basis that both are discussed with GLP-1 research.
Where is the dated development-status information?
Our REDEFINE 9 guide links the dated sponsor update. A study result, a conference presentation and a regulatory decision are separate events.
References
On November 20, 2026, we rechecked the parent-trial abstract, the sponsor’s subgroup counts and methods, the registry record and FDA's cagrilintide statement. The full subgroup posters, parent manuscript and participant-level data were not independently reviewed in this update. This is not a systematic review.
